You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms

    SBC: NEUROVASCULAR DIAGNOSTICS, INC.            Topic: 103

    Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Non-Clinical Pharmacology of CX-01

    SBC: Ceramedix Holding, LLC            Topic: NIAID

    Development of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as radiological dispersal devices (i.e., “dirty bomb”) and nuclear accidents, which may be caused by extreme weather (such as occurred in Fukushima, Japan in 2011). Radiation exposure can be potentially lethal via the hematopoietic-acute radiation syndrome (H-ARS) and the gastro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies

    SBC: Akeso Therapeutics Inc            Topic: 102

    PROJECT SUMMARY/ABSTRACTThe major hurdle in developing chimeric antigen receptor (CAR)-T therapy for T-cell malignancies is CAR-T cell fratricide by self-killing, which leads to insufficient numbers of CAR-T cells for infusion. CRISPR- mediated genomic editing provides an alternative approach to enabling expansion of CAR transduced T cells from allogeneic healthy donors. However, the safety and cl ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of B8C1ad as an Orphan Drug for Iatrogenic Botulism

    SBC: Cytodel, Inc.            Topic: 107

    Abstract Botulinum neurotoxin serotype A1 (BoNT/A1) has become an important therapeutic tool for multiple indications, despite being the most toxic protein known to science. Although serious Adverse Events (AEs) are rare, their importance is recognized by the Black Box warning included in the labeling for all FDA-approved BoNT/A1 products. During a recent 3-year period FDA received 13,087 AE repor ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies

    SBC: VITAN-BIOTECH LLC            Topic: 300

    Project SummaryA broad range of neurological indications, including schizophrenia, pain, Parkinson's and Alzheimer's diseases, and autism have been linked to G-protein coupled receptor proteins (GPCRs), making them attractive targets for therapy. Understanding GPCR dysfunction is essential for effective therapeutic development. However, deciphering the functions of GPCRs remains a daunting task in ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced Pediatric Airway Trainer for Enhanced Clinical Education in Pediatric Critical Care

    SBC: TDA RESEARCH, INC.            Topic: NICHD

    Project Summary/Abstract Clinical training aids such as surgical mannequins and procedural trainers are important tools for teaching proper technique to physicians and first responders. However, the majority of these training tools were developed for adult anatomies. Pediatric patients are often more challenging to treat, but few resources exist for advanced simulation in pediatric critical care e ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating

    SBC: Halomine Inc.            Topic: NIAID

    Project Summary/Abstract In the US, about 1.7 million Healthcare-Associated Infections (HAls) occur in hospitals each year, resulting in 99,000 deaths and an estimated $20 billion in healthcare costs. According to previous reports, as much as one third of HAI cases can be attributed to environmental surfaces, namely “high touch” surfaces (e.g., bed rails, machine buttons, equipment), in hospit ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a novel EEG-based index for evaluating amyloid and tau burden in Alzheimer's Disease

    SBC: Spark Neuro Inc.            Topic: NIA

    PROJECT SUMMARY Alzheimer’s disease (AD) is a progressive, neurodegenerative condition that impacts 44 million people globally. It is the most common cause of dementia—accounting for 80% of all dementia diagnoses—and predominantly affects older people. To date, AD has no cure. Thus, it is imperative to diagnose patients as early as possible to maximize the efficacy of symptom management stra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. In vivo high-definition 3D corneal imaging

    SBC: LighTopTech Corp.            Topic: NEI

    The cornea, the outermost window of our visual system, is vulnerable to various types of infections and diseases. Corneal disease is one of the leading causes of visual deficiency and blindness, and is considered the second major cause of blindness in developing countries. There are nearly 5 million bilaterally corneal blind persons worldwide, and an estimated 23 million people affected by unilate ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    Abstract. Bone marrow is one of the most radiation-sensitive tissues, and patients acutely exposed to total body irradiation (TBI) doses rt 2 Gy develop severe neutropenia, thrombocytopenia, anemia, and lymphopenia within days to weeks of exposure, often dying from infections (due to a lack of neutrophils) and uncontrolled bleeding (insufficient platelets) (referred to as the hematopoietic acute r ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government